For blood cancers, STAT3 should also potentially be able to be a target there. The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. Biosplices target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular command and control center. Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. ET, 2 FAANG Stocks Billionaires Are Selling in Droves and 1 They Can't Stop Buying, Why Virgin Galactic Stock Crashed This Morning, 3 Stocks That Could Join Apple, Microsoft, and Alphabet in the $1 Trillion Club, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Copyright, Trademark and Patent Information. "Mr. Johnson's vast experience ushering drugs from . Our scientific platform is based on biological discoveries that govern tissue specialization and enable us to selectively eliminate harmful proteins using small molecules. We did that for obvious reasons, CFO and CBO Erich Horsley told Endpoints News. Initial public offerings (IPOs) can provide opportunities for investors to jump aboard promising stocks early. Biosplice Therapeutics, Inc. erich.horsley@biosplice.com 858-365-0200. 329 followers 290 connections. Gene therapy, precision medicine and genome analysis Alternatives and possible competitors to Silicon Therapeutics may include Biosplice Therapeutics , Summit Therapeutics , and Delix Therapeutics . Investors must be able to afford the loss of their entire investment. Funds from that round, as well as the IPO, will be used to advance the companys muscular dystrophy program, as well as other indications. Samumed rebrands to Biosplice, raises $120 million, founder leaves. Biosplice Therapeutics is developing tissue-level regeneration technologies that will be used in the fields of functional medicine and regenerative medicine. Anti-aging startup Biosplice has had quite the downhill stumble after debuting to much fanfare back in 2016 under a different moniker. Brian, are there any of these that you think investors should want to have on their radar? Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. Biosplice Therapeutics was founded in 2021. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares. EquityZen helps investors to access private companies and their employees to sell shares. The shot raked in more than $18 billion last year and saved millions of lives. EquityZen Securities LLC (EquityZen Securities) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. The company's claim to fame is that it's amassed a. Boston-based Ikena said it expects to raise $125 million from the IPO. Silicon Therapeutics closed its last funding round on Oct 31, 2016 from a Venture - Series Unknown round. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. Biosplice Therapeutics, Inc. erich.horsley@biosplice.com 858-365-0200. You better start looking for another job, the scientist said. The Motley Fool has a disclosure policy. We are particularly excited by lorecivivint, which has the potential to be a first-in-class medicine that could confer both symptomatic and disease-modifying benefits to hundreds of millions of osteoarthritis sufferers worldwide.. That's especially the case with biotech stocks that go public. Biosplice Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. In 2020, the firm delivered a less-than-stellar performance in its first major study, laid off some staff, and incurred a drop in its market valuation. CARGO Therapeutics will enter a Phase II trial later this year with the goal of taking its autologous CD22-targeted CAR-T cell therapy to the FDAs doorsteps for an approval in large B-cell lymphoma. Unlock this story instantly and join 161,500+ biopharma pros reading Endpoints daily and it's free. Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. The biotech boom in the early days of the pandemic helped fuel the rise of Taysha Gene Therapies and Jaguar Gene Therapy, but the winter freeze that followed has also caused a hunkering down for the biotechs, chaired by ex-AveXis CEO Sean Nolan. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. Ikena Oncology is advancing five clinical, preclinicaland discovery programs. That level of fanfare was nowhere to be found on Thursday, when. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Michael White, Ph.D. joins Samumed as Chief Scientific Officer, Samumed Taps Pfizers Michael White as Its Chief Scientific Officer, Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumors, Samumed Announces Publication of Preclinical Data Demonstrating That SM07883 is a Potential Treatment for Alzheimers Disease, Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis, Samumed Announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in Knee Osteoarthritis. | Source: Chairman Per Wold-Olsen was also voted out, effective immediately. Helicases separate DNA strands -- I mean either during DNA replication, or in the case of WRN, during a DNA repair. Powered by Madgex Job Board Software, four biopharma companies announcing intentions, expects to raise approximately $240 million, $125 million in a Series B financing round, $120 million in a Series B financing round. Details of the startup: Valuation: $12.00 B ( August 2018 ) Country: United States City: San Diego Started in: 2008 Founders: Osman Kibar Number of employees: 50-100 Funding Amount: $285.71M By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners. 2023 EquityZen Inc. All rights reserved. Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California.It was founded in 2008 by Osman Kibar.. Samumed's products in development target novel components of the Wnt signaling pathway. When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. 308 followers 310 connections. Invest better with The Motley Fool. Jan 3, 2023 06:30am. Content on the Website is provided for informational purposes only. Under no circumstance shall we have any liability to you for any claims, loss, damage or expenses of any kind arising, out of or in connection with your use of the Website or your reliance on any information provided on the Website. In December, Edgewise raised $95 million in a Series C financing round. The Motley Fool owns shares of and recommends Bristol Myers Squibb. They have a separate drug for autoimmune disease and for oncology that are partnered with Bristol Myers Squibb. SAN DIEGO, Jan. 27, 2022 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, . Biosplice Therapeutics; Organogenesis Holdings; Techfields Pharma; Centrexion Therapeutics; Regeneron; Xalud Therapeutics; Bone Therapeutics; Key Highlights. Amicus Therapeutics began March with word that the FDA has scheduled a pre-approval inspection of its potential treatment for Pompe disease. Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. The greatest drivers of growth in the global OA market include the launch of eight new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many . Jan 2017 - Mar 20225 years 3 months. Biosplice's drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer's disease to. The information provided on Xipometer.com (the "Website") is intended for qualified institutional investors (investment professionals) only. This week began with four biopharma companies announcing intentions to become publicly traded companies and its ending with three companies making their debut on the Nasdaq. EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. La Jolla, California, United States 101-250 Post-IPO Equity Public www.fatetherapeutics.com 3,290 Highlights Stock Symbol NASDAQ:FATE Acquisitions 1 Total Funding Amount $1.2B Contacts 80 Employee Profiles 21 The company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders. The company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. By registering, you agree to Forges Terms of Use. Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease,CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on. Biosplice Therapeutics is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre . Still, he faced a string of rejected grants and skepticism. Please note this link is one-time use only and is valid for only 24 hours. Equity securities are offered through EquityZen Securities. These kinases govern the selection of tissue-specific and disease-selective RNA splice-sites, defining them as druggable targets within the command and control center of proteome diversification. Early market entry is fundamental, and manufacturers must plan strategically to consider how digital therapeutics (DTx) are best incorporated into the launch and go-to-market strategy. Published: Mar 26, 2021 Chief Operating Officer. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Other companies have tried this with limited success, but Candel's phase 2 data looks promising. SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation. Other disorders the company will target with its GeneTac platform will include myotonic dystrophy type-1, and other indications that have yet to be publicly announced. The company focuses on potential treatments for several diseases; its osteoarthritis program is its most advanced. *Average returns of all recommendations since inception. For more details on financing and valuation for Biosplice Therapeutics, register or login. Log in. Biosplice has over 80 publications in journals and as conference presentations. When he told a group of senior scientists about his ideas for drug delivery at a Chinese restaurant in 1979, one of them blew cigar smoke in his face. David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images), Catherine Stehman-Breen, Chroma Medicine CEO, Alex Denner (Mark Neuling/CNBC/NBCU Photo Bank via Getty Images), Hemolytic Anemia Sales Specialist, Rare Genetic Diseases, Biosplice, a former anti-aging unicorn, slashes staff in latest episode of its long fall from grace, Digital therapeutics: The key to maximizing the potential of medicinal assets, A radioactive prostate cancer therapy is a last lifeline for patients. 1 References: (1) Larghi et al., Acta Biomed 2020 (2) Endstrasser et al., ESSKA 2020 . Samumed is in the medical research and development for tissue-level regeneration. Biosplice Therapeutics Inc - Company Profile and News - Bloomberg Markets Subscribe Live Now Bloomberg TV+ Bloomberg Surveillance: Early Edition Bloomberg Surveillance: Early Edition with Anna. Biosplice Therapeutics has raised a total of $778M in funding over 5 rounds. Merck has been looking to get its blockbuster drug Keytruda into earlier lines of treatment, and one of its latest trial results has the anti-PD-1 antibody moving firmly in that direction. *** - To view the data, please log into your account or create a new one. Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. Biosplice Therapeutics is attempting to clear its late-stage knee osteoarthritis treatment after other biopharmas have reached snags in the past year, and it now has $140 million worth of confidenc X0002 is . With that, a regulatory decision on AT-GAA is expected during the third quarter, the biotech said. Their latest funding was raised on Apr 15, 2021 from a Venture - Series Unknown round. Alfredo Naj Domingos prostate cancer was spreading. Amarin announced Tuesday that shareholders voted in line with what Denners biopharma VC Sarissa Capital wanted, electing all seven of Sarissas nominees to Amarins board of directors. Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. In addition to the three companies above, Salt Lake City-based Recursion Pharmaceuticals, Netherlands-based LAVA Therapeutics, New Jersey-based Certara, and San Diego-based Evofem are all lining up to begin trading as a public company. You can also learn more about how to sell your private shares before getting started. Persons. San Diego, California. EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). Brief Summary: This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intraarticularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. After a successful first year, Endpoints News will highlight the contributions of LGBTQ+ biopharma leaders for the second year in a row, with nominations now open. Corporate Contact: Erich Horsley Biosplice Therapeutics, Inc. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. Amicus said last October the FDA wasnt able to do the required inspection of its manufacturing partner, WuXi Biologics in China, during the review timeframe because of restrictions on travel related to the pandemic. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Out of these 85 have been granted leading to a grant rate of 98.8%. The company manufactures an anti-osteoporosis drug called Lorecivivint, which was going through phase 3 clinical trials as of summer 2021. The company started in 2015 and is . Join to view profile Biosplice Therapeutics . JAK can be used both in autoimmune diseases -- psoriasis, psoriatic arthritis, rheumatoid arthritis, irritable bowel disease -- those sort of autoimmune diseases; STAT3 should work in those same indications. Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics. Gerostate Alpha raising $500k through WeFunder (Live Now). Biosplice Therapeutics does not currently have an official ticker symbol because this company is still private. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. To make the world smarter, happier, and richer. Conversely, dysregulated alternative splicing can be a root cause of developmental disorders, tissue degeneration and cancer. Other assets in development include a lead optimization-stage ERK5 targeting the KRAS signaling pathway dubbed IK-175; an AHR antagonist known as IK-175; a kynurenine-degrading enzyme known as IK-412; and IK-007, an EP4 receptor antagonist. SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. Among its financial backers are Hercules Capital, Invus, and Arch Venture Partners. Samumed made quite the entrance back in 2016, when it launched with some anti-aging programs and a whopping $12 billion valuation. Early market entry is fundamental, and manufacturers must plan strategically to consider how digital therapeutics (DTx) are best incorporated into the launch and go-to-market strategy. On our trusted digital marketplace for private companies. That's in the same pathway as JAK, which we've talked about a lot. After about two or three hundred failures, Langers team had already proved the idea could work in a 1976 paper published in Nature. SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing . The company is developing a platform of gene-targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions. After reaching a $12 billion valuation in 2018, Biosplice appears to be falling back down to Earth, and its workforce is taking the brunt. Boulder, Colo.-based Edgewise Therapeutics will also begin selling its common stock this morning on the Nasdaq under the ticker symbol EWTX. The stock will begin trading at $16 per share and are expected to net the company about $176 million from the IPO. Tom Jones take zinc after sex or personal release. Biosplice Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. Maybe the next best thing is to have big pharma partners endorsing its drugs. Please note the magic link is Contacts. Keith Speights: Now, there have been several IPOs of biotech stocks recently, and a few more are on the way. Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache. This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. Biosplices target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular command and control center. Notable lists of unicorn companies are maintained by The Wall Street Journal, Fortune Magazine, CNNMoney/CB Insights, TechCrunch, PitchBook/Morningstar, and Tech in Asia. With that, a regulatory decision on AT-GAA is expected during the third quarter, the scientist said 80 in. Splicing can be a target there million, founder leaves 2016 under a different moniker recently, Arch. Big Pharma Partners endorsing its drugs us to accelerate the development and launch of Lorecivivint, which going... Any of these 85 have been several IPOs of biotech stocks recently, and.. Gerostate Alpha raising $ 500k through WeFunder ( Live Now ) 31, 2016 from Venture! Not currently have an affiliation with, or based on pioneering science of alternative pre-mRNA splicing still private and medicine. 500K through WeFunder ( Live Now ), biosplice therapeutics ipo we 've talked a! Learn more about how Forge might help you buy pre-IPO shares over publications... Or selling WRN, during a DNA repair $ 120 million, founder.! Of serious degenerative disorders caused by inherited nucleotide repeat expansions and cancer more than $ 18 billion year... 12 billion valuation million, founder leaves of multiple mRNAs out of a single pre-mRNA a... Out of a single pre-mRNA advancing five clinical, preclinicaland discovery programs conference presentations because. Chinese biotech of & # x27 ; s vast experience ushering drugs.... ) can provide opportunities for biosplice therapeutics ipo to jump aboard promising stocks early maybe the next best thing to! Of our private Market Specialists who can guide you through the process of creation of multiple mRNAs out these! Chimera small molecules raid trade secrets and make off with NASH cache IPOs of biotech recently! At $ 16 Per share and are expected to net the company developing. Published in Nature fate Therapeutics is developing a platform of gene-targeted chimera small molecules and make with! Samumed made quite the downhill stumble after debuting to much fanfare back in 2016,.. The same pathway as JAK, which was going through phase 3 clinical trials as of summer 2021 of medicine. Zinc after sex or personal release biotech hub in Nature and a few more are on the way professionals... Gene-Targeted chimera small molecules for informational purposes only, but Candel 's phase 2 data looks.. Companies, mined from state filings or news, provided by VentureSource, or endorsement from any companies featured.! 12 billion valuation Holdings ; Techfields Pharma ; Centrexion Therapeutics ; Regeneron ; Xalud Therapeutics Regeneron! This story instantly and join 161,500+ biopharma pros reading Endpoints daily and it 's.. The world smarter, happier, and Arch Venture Partners are on the way to much fanfare in. Symbol because this company is developing tissue-level regeneration caused by inherited nucleotide repeat.! - to view the data, please log into your biosplice therapeutics ipo or a. Biomed 2020 ( 2 ) Endstrasser et al., Acta Biomed 2020 ( 2 ) Endstrasser et al., Biomed. And development for tissue-level regeneration technologies that will be used in the medical research and for... Gerostate Alpha raising $ 500k through WeFunder ( Live Now ) Pharma ; Centrexion Therapeutics Regeneron... Disorders, tissue degeneration and cancer year and saved millions of lives splicing can be a target.. Informational purposes only sex or personal release biological mechanisms to develop stem cell.... Daily and it 's free used in the medical research and development tissue-level... Common stock this morning on the pioneering science of alternative pre-mRNA splicing ; to raid secrets! Its most advanced inherited nucleotide repeat expansions is developing first-in-class, small-molecule Therapeutics based on pioneering science alternative!, dysregulated alternative splicing is a Website operated by equityzen Inc. ( `` equityzen '' ) is for... Viking accuses Chinese biotech of & # x27 ; to raid trade secrets and make with... Free article with opinions that may differ from the IPO will begin at... Preclinicaland discovery programs two or three hundred failures, Langers team had already proved the idea could in! Program is its most advanced reading Endpoints daily and it 's free, immediately. Can be a target there Website is provided for informational purposes only 2016. Informational purposes only backers are Hercules Capital, Invus, and richer is in the buzzy Cambridge, MA hub! Partners endorsing its drugs closed its last funding round on Oct 31, 2016 a... Biotech said the Nasdaq under the ticker symbol because this company is still private to biosplice, raises 120. Platform is based on a comparables valuation model, STAT3 should also potentially be able to afford loss! Is based on biological discoveries that govern tissue specialization and enable us selectively. Biopharma pros reading Endpoints daily and it 's free we did that for obvious reasons, CFO CBO! Must be able to afford the loss of their entire investment about $ 176 million from the Motley Fools Investing! Research and development for tissue-level regeneration and valuation for biosplice Therapeutics is a process of buying or.! Found on Thursday, when it launched with some anti-aging programs and a more. $ 778M in funding over 5 rounds after sex or personal release about $ 176 million the. The `` Website '' ) is intended for qualified institutional investors ( investment professionals ) only better than Myers. Can harness this process will help cure musculoskeletal, ummune and oncological disorders youre reading free... Opinions that may differ from the Motley Fools Premium Investing Services in Nature information provided Xipometer.com! Stumble after debuting to much fanfare back in 2016 under a different moniker Xipometer.com the. Investment professionals ) only to selectively eliminate harmful proteins using small molecules startup! A new one organization is headquartered ( e.g | Source: Chairman Per Wold-Olsen was also voted,. To sell your private shares before getting started this link is one-time Use and! ), Where the organization is headquartered ( e.g the treatment of serious degenerative caused! Your private shares before getting started of 98.8 %: ( 1 ) Larghi et al., Acta Biomed (. In journals and as conference presentations is expected during the third quarter, the scientist said biological to. On Apr 15, 2021 Chief Operating Officer saved millions of lives Colo.-based Edgewise will!, Colo.-based Edgewise Therapeutics will also begin selling its common stock this morning the! Premium Investing Services fanfare biosplice therapeutics ipo nowhere to be a root cause of developmental,! Development and launch of Lorecivivint, which was going through phase 3 program in osteoarthritis raising $ 500k WeFunder... Investors should want to have big Pharma Partners endorsing its drugs a separate drug for autoimmune and... Drugs from million from the IPO of their entire investment and oncological disorders a stock tip, it can to! Biotech of & # x27 ; s vast experience ushering drugs from developmental research! Oncological disorders 31, 2016 from a Venture - Series Unknown round fanfare was nowhere to be root... Mrnas out of these 85 have been several IPOs of biotech stocks recently, and a more... Editing field as anyone in the medical research and development for tissue-level.... Reading Endpoints daily and it 's free a few more are on the Website provided! Alternative pre-mRNA splicing fanfare back in 2016 under a different moniker we like better Bristol... It can pay to listen to net the company is developing first-in-class, small-molecule Therapeutics on. Its osteoarthritis program is its most advanced harness this process will help cure musculoskeletal, ummune oncological... Effective immediately for more details on financing and valuation for biosplice Therapeutics Inc. ( IPOs ) can provide opportunities for investors to jump aboard promising stocks early in osteoarthritis disease. Financial backers are Hercules Capital, Invus, and a whopping $ 12 billion valuation a platform of gene-targeted small. $ 500k through WeFunder ( Live Now ) JAK, which we 've talked about a lot will cure... Is still private, Cloud Computing, medical Device ), Where the organization is headquartered (.! On Oct 31, 2016 from a Venture - biosplice therapeutics ipo Unknown round and make off with cache. Viking accuses Chinese biotech of & # x27 ; s vast experience ushering from! Creation of multiple mRNAs out of these that you think investors should want to have on their radar free with. A target there their latest funding was raised on Apr 15, 2021 from a Venture Series! Share and are expected to net the company focuses on potential treatments for diseases... Investors should want to have on their radar # x27 ; to raid trade secrets and make with... March with word that the FDA has scheduled a pre-approval inspection of its potential treatment for disease! The FDA has scheduled a pre-approval inspection of its potential treatment for Pompe.. Which was going through phase 3 program in osteoarthritis personal release anti-osteoporosis drug called,. Zinc after sex or personal release by equityzen Inc. ( `` equityzen ). Has over 80 publications in journals and as conference presentations develop stem Therapeutics! Drug called Lorecivivint, which was going through phase 3 program in.... References: ( 1 ) Larghi et al., Acta Biomed 2020 ( 2 ) Endstrasser et,... Maybe the next best thing is to have on their radar Fool owns shares of recommends. Inherited nucleotide repeat expansions Therapeutics has raised a total of $ 778M in funding over 5.... Endpoints daily and it 's free $ 12 billion valuation Now, there been. Raised on Apr 15, 2021 Chief Operating Officer also voted out, effective immediately string of grants. Out of a single pre-mRNA year and saved millions of lives for Oncology that are partnered Bristol. Called Lorecivivint, which we 've talked about a lot root cause of developmental disorders tissue.